Skip to main content
Clinical Trials/CTRI/2021/11/038197
CTRI/2021/11/038197
Not yet recruiting
未知

A comparative study of safety, efficacy and correlation with non-invasive break up time using two fluorescein dyes in subjects undergoing dry eye evaluation for pre-refractive surgery work up

BioTech Vision Care Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: H048- Other disorders of lacrimal system
Sponsor
BioTech Vision Care Pvt Ltd
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
BioTech Vision Care Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\. Any patient presenting to refractive surgery clinic for refractive surgery clinic for refractive surgery work up within the age group of 20\-40 years with normal ocular surface.
  • 2\. Clear corneas without scarring, opacities, or vascularization as determined by bio microscopic examination; normal puncta without punctal plugs or punctal stenosis; and the absence of any corneal disease or dystrophy
  • 3\. Able to give written consent form

Exclusion Criteria

  • 1\. Any patient of known ocular surface abnormality or corneal abnormality
  • 2\. History of ocular surgery or corneal injury
  • 3\. Active infection or allergy
  • 4\. Conjunctival abnormality other than mild pinguecula
  • 5\. Current use of any ocular medication, including antihistamines
  • 6\. Use of artificial tear preparations 2 hours prior to examination
  • 7\. Use of any ocular ointment, swimming in chlorinated water or 24 hours prior to examination
  • 8\. Contact Lens wearers\- Soft contact Lens \<48 hours, rigid gas permeable lens \<2 weeks
  • 9\. Patient on any ocular medications
  • 10\. Any patient having known hypersensitivity to Fluorescein dye

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 4
Comparison of the efficacy and safety of tamsulosin OCAS with tamsulosin MR and placebo in improving lower urinary tract symptoms
IRCT20100817004582N8rology Research Centre, Guilan University of Medical Sciences260
Completed
Phase 4
Comparison of the seizure drug levetiracetam with controlled release carbamazepine in new focal seizure patientsHealth Condition 1: G400- Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onsetHealth Condition 2: G402- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizuresHealth Condition 3: G401- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
CTRI/2019/05/018990Institutional sponsored74
Active, not recruiting
Not Applicable
Dexmedetomedine intravenous sedation on patients with and without Beta blockersHealth Condition 1: null- Retinal Disorder Patients requiring SurgeryHealth Condition 2: H431- Vitreous hemorrhage
CTRI/2018/08/015387ETHRADHAMA SUPER SPECIALITY EYE HOSPITA
Recruiting
Phase 3
Comparative assessment of the efficacy and safety of add ontreatment with Sofosbuvir standard of care therapeutic regimenVelpatasvir” to standard of caretherapeutic regimen” in patients with COVID-19COVID-19.COVID-19 diseaseU07.1
IRCT20130812014333N145Kermanshah University of Medical Sciences80
Recruiting
Phase 3
Comparative assessment of the efficacy and safety of addon treatment with Sofosbuvir-Daclatasvir”, Lithium”,and Trifluoprazine” to standard of care in three groups of patients with COVID-19
IRCT20130812014333N147Kermanshah University of Medical Sciences80